Anand A Dalal
Overview
Explore the profile of Anand A Dalal including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
78
Citations
1352
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Yang H, Bollu V, Lim S, Tesfaye M, Dalal A, Lax A, et al.
Leuk Lymphoma
. 2022 Nov;
64(2):339-348.
PMID: 36408973
Chimeric antigen receptor T-cell (CAR-T) infusion settings may impact healthcare resource use (HRU) and reimbursement amounts. Adults with diffuse large B-cell lymphoma receiving CAR-T therapy were identified from the Centers...
2.
Biskupiak J, Oderda G, Brixner D, Tang D, Zacker C, Dalal A
J Manag Care Spec Pharm
. 2019 Jul;
25(8):859-866.
PMID: 31347980
Background: Discarding unused drugs after dose changes or discontinuation can significantly affect pharmacy budgets. This is especially concerning for expensive oncology agents. However, few economic studies account for drug wastage,...
3.
Patterson-Lomba O, Dalal A, Ayyagari R, Liu O, Dervishi E, Platt E, et al.
Breast J
. 2019 Jul;
25(5):880-888.
PMID: 31290203
Several endocrine-based therapies have recently been evaluated as treatments for premenopausal women with hormone-receptor-positive/human-epidermal-growth-factor-receptor 2 negative (HR+/HER2-) metastatic breast cancer (mBC). We conducted a systematic review and assessed the feasibility...
4.
Yardley D, Hart L, Favret A, Blau S, Diab S, Richards D, et al.
Clin Breast Cancer
. 2019 Jun;
19(4):268-277.e1.
PMID: 31160171
Background: In the Mammary Oncology Assessment of LEE011's (Ribociclib's) Efficacy and Safety (MONALEESA-2) study, combination treatment with the selective inhibitor of cyclin-dependent kinases 4/6 ribociclib with letrozole significantly improved progression-free...
5.
Dalal A, Gauthier G, Gagnon-Sanschagrin P, Burne R, Guerin A, Niravath P, et al.
Adv Ther
. 2018 Aug;
35(9):1356-1367.
PMID: 30105655
Introduction: Premenopausal women with hormone receptor positive (HR+) and human epidermal growth factor receptor-2-negative (HER2-) advanced breast cancer (aBC) often present with aggressive tumor types that lead to poor prognosis,...
6.
Patel J, Coutinho A, Lunacsek O, Dalal A
Int J Chron Obstruct Pulmon Dis
. 2018 Aug;
13:2301-2311.
PMID: 30104870
Purpose: This study aimed to measure the true burden of COPD by calculating incremental direct and indirect costs. Direct medical resource use, productivity metrics, and COPD-specific resource use and costs...
7.
Mistry R, Suri G, Young K, Hettle R, May J, Brixner D, et al.
Curr Med Res Opin
. 2018 Jul;
34(12):2143-2150.
PMID: 30032697
Objectives: The combination of a cyclin-dependent kinase 4 and 6 (CDK 4/6) inhibitor with the aromatase inhibitor letrozole is a safe and effective alternative to letrozole monotherapy for first-line hormone...
8.
Guerin A, Goldschmidt D, Small T, Gagnon-Sanschagrin P, Romdhani H, Gauthier G, et al.
Adv Ther
. 2018 Jun;
35(8):1251-1264.
PMID: 29946797
Introduction: In the treatment of metastatic breast cancer (mBC), regular monitoring is key in helping physicians to make informed clinical decisions, managing treatment side effects, and maintaining patients' quality of...
9.
Dalal A, Gagnon-Sanschagrin P, Burne R, Guerin A, Gauthier G, Small T, et al.
Adv Ther
. 2018 Jun;
35(6):768-778.
PMID: 29869106
Introduction: Targeted therapies have revolutionized the treatment of hormone receptor positive/human epidermal growth factor receptor 2 negative (HR+/HER2-) metastatic breast cancer (mBC). However, as for many oncology drugs, the dose...
10.
Mistry R, May J, Suri G, Young K, Brixner D, Oderda G, et al.
J Manag Care Spec Pharm
. 2018 May;
24(6):514-523.
PMID: 29799329
Background: U.S. regulatory approvals of the cyclin-dependent kinase 4 and 6 (CDK 4/6) inhibitors ribociclib and palbociclib as add-ons to letrozole greatly enhance the prospects for treating postmenopausal women with...